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P

revention of diabetes, as well as early
detection and treatment of both prediabetes and diabetes, is critical to
the health of our country. Because evidencebased guidelines are key to our ability to
effectively address the nation’s diabetes epidemic, the American Diabetes Association
(ADA) updates its “Standards of Medical Care
in Diabetes” annually to incorporate new evidence or clarifications.
The 2016 standards,1 available at professional.diabetes.org/jfp, are a valuable
resource. Among the latest revisions: an expansion in screening recommendations, a
change in the age at which aspirin therapy for
women should be considered, and a change in
A1C goals for pregnant women with diabetes.
As members of the ADA’s primary care
advisory group, we use a question and answer format in the summary that follows to
highlight recent revisions and review other
recommendations that are of particular relevance to physicians in primary care. It is
important to note, however, that ADA recommendations are not intended to preclude
clinical judgment and should be applied in
the context of excellent medical care.

Diagnosis and screening
Have the 2016 ADA standards changed
the way diabetes is diagnosed?
No. The criteria for a diagnosis of diabetes
did not change. Diabetes and prediabetes
are still screened for and diagnosed with
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any of the following: a fasting plasma glucose (FPG); a 2-hour 75-g oral glucose tolerance test (OGTT); a random plasma glucose
>200 mg/dL with symptoms of hyperglycemia;
or A1C criteria (TABLE 1).1,2 The wording was
changed, however, to make it clear that no one
test is preferred over another for diagnosis.
Have screening recommendations
been revised?
Yes. In addition to screening asymptomatic
adults of any age who are overweight or obese
and have one or more additional risk factors
for diabetes, the 2016 standards recommend
screening all adults 45 years and older, regardless of weight.
Is an A1C <7% the recommended
treatment goal for everyone with diabetes?
No. An A1C <7% is considered reasonable for
most, but not all, nonpregnant adults. In the
last few years, the ADA has focused more on
individualized targets.
Tighter control (<6.5%)—which is associated with lower rates of eye disease, kidney
disease, and nerve damage—may be appropriate for patients who have no significant
hypoglycemia, no cardiovascular disease
(CVD), a shorter duration of diabetes, or a
longer expected lifespan.
Conversely, a higher target (<8%) may be
appropriate for patients who are older, have
longstanding diabetes, advanced macrovascular or microvascular disease, established complications, or a limited life expectancy.3,4
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❚ Pregnancy. The 2016 standards have
a new target for pregnant women with diabetes: The ADA previously recommended
an A1C <6% for this patient population, but
now recommends a target A1C between 6%
and 6.5%. This may be tightened or relaxed,
however, depending on individual risk of
hypoglycemia.
In focusing on individualized targets and
hypoglycemia avoidance, the ADA notes that
attention must be paid to fasting, pre-meal,
and post-meal blood glucose levels to achieve
treatment goals. The 2016 standards emphasize the importance of patient-centered
diabetes care, aligned with a coordinated,
team-based chronic care model.
Diabetes self-management education and
support is indicated for those who are newly diagnosed, and should be provided periodically
based on glucose control and progression of
the disease. All patients should receive education on hypoglycemia risk and treatment.

impaired fasting glucose, or an A1C between
5.7% and 6.4% are considered to have prediabetes and are at risk for developing type 2
diabetes.
Family physicians should refer patients
with prediabetes to intensive diet, physical activity, and behavioral counseling programs like those based on the Diabetes
Prevention Program study (www.niddk.nih.
gov/about-niddk/research-areas/diabetes/
diabetes-prevention-program-dpp/Pages/
default.aspx). Goals should include a minimum
7% weight loss and moderate-intensity physical activity, such as brisk walking, for at least
150 minutes per week.
Lifestyle modification programs have
been shown to be very effective in preventing diabetes, with about a 58% reduction in
the risk of developing type 2 diabetes after
3 years.5 The 2016 standards added a recommendation that physicians encourage the use
of new technology, such as text messaging or
smart phone apps, to support such efforts.

Prediabetes and prevention

Should I consider initiating oral
antiglycemics in patients with prediabetes?
Yes. Pharmacologic agents, including metformin, acarbose, and pioglitazone, have been
shown to decrease progression from predia-

What is prediabetes and what can I do
to prevent patients with prediabetes
from developing diabetes?
Patients with impaired glucose tolerance,
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TABLE 1

Criteria for the diagnosis of prediabetes and diabetes1,2
Prediabetes

Diabetes

A1C

5.7%-6.4%

≥6.5%*

FPG

100-125 mg/dL (5.6-6.9 mmol/L)

≥126 mg/dL (7 mmol/L)*

OGTT

140-199 mg/dL (7.8-11 mmol/L)

≥200 mg/dL (11.1 mmol/L)*

RPG

≥200 mg/dL (11.1 mmol/L)**

FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; RPG, random plasma glucose.
*In the absence of unequivocal hyperglycemia, results should be confirmed by repeating the test.
**Random plasma glucose is diagnostic only in a patient with classic symptoms of hyperglycemia or hyperglycemic crisis.

For patients
with diabetes,
a sustained
weight loss
of 5% may
improve
glycemic control
and reduce
the need
for medication.

betes to type 2 diabetes. Thus, antiglycemics
should be considered for certain patients. Metformin is especially appropriate for women
with a history of gestational diabetes, patients
who are younger than 60 years, and those who
have a body mass index (BMI) ≥35 kg/m2.6
How often should I screen patients
with prediabetes?
Patients with prediabetes should be screened
annually. Such individuals should also be
screened and treated for modifiable cardiovascular risk factors. There is strong evidence
that the treatment of obesity can be beneficial for those at any stage of the diabetes
spectrum.

Obesity management
What do the 2016 ADA standards
recommend for obese patients
with diabetes?
With more than two-thirds of Americans either overweight or obese, the ADA added
a new section on obesity management and
calls on health care providers to:
• weigh patients and calculate and document their BMI at every visit, and
• counsel those who are overweight or
obese on the benefits of even modest
weight loss.

The ADA recommends a sustained
weight loss of 5%, which can improve glycemic control and reduce the need for diabetes
medications,7-9 although weight loss of ≥7%
is optimal. Physicians are also called on to
assess each patient’s readiness to engage in
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therapeutic lifestyle change to maintain a
modest weight loss.
Treatment for obesity can include therapeutic lifestyle change (reduction in calories,
increase in physical activity) and behavioral
therapy. For refractory patients, pharmacologic therapy and bariatric surgery may be
considered.
Interventions should be high-intensity
(≥16 sessions in 6 months) and focus on diet,
physical activity, and behavioral strategies to
achieve a 500 to 750 calorie deficit per day.10
Long-term (≥1 year) comprehensive weight
maintenance programs should be prescribed
for those who achieve short-term weight
loss.11,12 Such programs should provide at
least monthly contact and encourage ongoing
monitoring of body weight (weekly or more
frequently), continued consumption of a reduced-calorie diet, and participation in high
levels of physical activity (200 to 300 minutes
per week).

Glycemic treatment
What are some of the key factors
that distinguish the different type 2
diabetes medications from one another?
An increasing understanding of diabetes
pathophysiology has led to a wider array of
medications, making treatment more complex than ever. It is important for physicians
to have a strong working knowledge of the
various classes of antidiabetic agents and the
subtleties between drugs in the same class to
best individualize treatment.
Here are the highlights of each class
of medication listed in the ADA/European
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Association for the Study of Diabetes algorithm for the management of type 2 diabetes,13 which is available at http://care.
diabetesjournals.org/content/38/1/140/
F2.large.jpg):
❚ Metformin is the preferred initial medication for all patients who can tolerate it and
have no contraindications. The drug is costeffective, weight neutral, and has had positive cardiovascular and mortality outcomes
in long-term studies. Adverse gastrointestinal
(GI) effects, including nausea, diarrhea, and
dyspepsia, are common but can be reduced
with a slow titration of the drug. Metformin
should be used with caution in those with renal disease. The dose should be reduced if the
estimated glomerular filtration rate (eGFR)
<45 mL/min/1.73m2 and the drug discontinued if eGFR <30 mL/min/1.73 m2.
❚ Sulfonylureas/meglitinides stimulate
insulin secretion in a glucose-independent
manner. They are cost-effective and have
high efficacy early in the disease and with
initial use, but the effect wanes as the disease progresses. This class of drugs is associated with weight gain and hypoglycemia.
Second-generation sulfonylureas (glipizide,
glimepiride) are recommended; meglitinides
are more expensive than sulfonylureas.
❚ Thiazolidinediones work to improve
insulin sensitivity in the periphery and have
a low risk of hypoglycemia. They have been
associated with fluid retention, weight gain,
and worsening of pre-existing congestive
heart failure, but previous cardiovascular
concerns (with rosiglitazone)14 and bladder cancer risks (with pioglitazone)15-17 have
been refuted. Thiazolidinediones are contraindicated in those with Class III and IV congestive heart failure, however, and patients
taking them require careful monitoring for
weight gain, fluid retention, and exacerbation
of heart failure.
❚ Dipeptidyl peptidase-4 inhibitors
(DPP4Is) work to reduce the breakdown of

endogenous incretin hormones. These oral
agents increase insulin secretion in a glucose-dependent manner; more insulin is secreted when glucose is higher and less when
glucose is closer to normal. This means that
there is a much lower risk of hypoglycemia
when a DPP4I is used as monotherapy.

❚ Glucagon-like peptide 1 receptor
agonists (GLP-1RAs), which are injectable,

also work via incretin hormones and stimulate insulin in a glucose-dependent manner.
They are associated with weight loss and low
rates of hypoglycemia. Adverse GI effects are
common with this class of drugs, but can
be reduced by titrating the medication and
avoiding overeating. GLP-1RAs can be taken
twice daily to once weekly, depending on the
specific agent.
❚ Sodium glucose transporter 2 inhibitors (SGLT2Is) are oral agents and the newest

class of antidiabetes drugs. The drugs help
block the reabsorption of glucose, thereby
lowering glucose levels, blood pressure, and
weight in many patients. The most common
adverse effects are urinary tract and genital
yeast infections. SGLT2Is should not be given to patients with advanced renal disease
(chronic kidney disease Stages 3B-5) because
they will not be effectively absorbed.
The US Food and Drug Administration
(FDA) recently issued a warning about the risk
of ketoacidosis with these agents,18 and patients should be advised to stop taking them
and to seek immediate medical attention if
they develop symptoms of ketoacidosis, such
as excessive thirst, frequent urination, nausea
and vomiting, abdominal pain, weakness or
fatigue, shortness of breath, fruity-scented
breath, or confusion.
❚ Insulin is eventually needed by most
patients with type 2 diabetes who live long
enough to see the disease progress. The most
common adverse effects are weight gain and
hypoglycemia. There are many types of insulin, but only one that is delivered via inhalation—human insulin inhaled powder.
Inhaled insulin, however, has the potential
for adverse pulmonary effects, including
cough and reduction of peak expiratory flow.
Therefore, pulmonary function testing is recommended prior to its use.
Treatment goal attainment should be
evaluated every 3 months, and treatment titrated at 3-month intervals if goals are not
achieved. The ADA/European Association
for the Study of Diabetes’ algorithm indicates
that patients are likely to need insulin a year
after diagnosis if their A1C goal has not been
achieved or maintained.13

Patients who
fail to achieve
or maintain their
A1C goal after
one year may
need to begin
insulin therapy.

C ON TIN U ED
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Patients
≥40 years will
need moderateto high-intensity
statin therapy
to lower their
atherosclerotic
cardiovascular
disease risk.

The following medications are not included in the algorithm but are included in
the 2016 standards, and may be helpful for
certain patients:
❚ Alpha-glucosidase inhibitors delay the
absorption of glucose from the proximal to
distal GI tract, thereby reducing postprandial
hyperglycemia. Flatulence and leakage of
stool—the most common adverse effects—
have limited their use in the United States.
❚ Bile acid sequestrants (colesevelam)
treat both hyperlipidemia and diabetes.
The medications work by reducing glucose
absorption from the GI tract. They reduce
postprandial hyperglycemia, with a low risk
of hypoglycemia. Colesevelam’s use is limited, however, because of the number of pills
needed (6 daily).
❚ Bromocriptine affects satiety levels
via the central nervous system, and is available in a specific formulation for the treatment of diabetes. “First-dose” hypotension,
however, is an adverse effect of considerable
concern.1
❚ Pramlintide, an injectable amylin mimetic given to patients on prandial insulin,
can reduce postprandial glucose levels. The
most common adverse effects are upper GI
symptoms and hypoglycemia. Due to the adverse effects and the need for an injection with
each meal, pramlintide is used infrequently.

Cardiovascular risk reduction
Has the ADA revised its recommendations
for cardiovascular disease risk
management?
Yes. There have been several changes. The
first is in terminology, with atherosclerotic
cardiovascular disease (ASCVD) replacing CVD alone. While new recommendations for statin therapy for adults older than
40 years (TABLE 2 )1 were also added, the emphasis remains on therapeutic lifestyle change
as an effective treatment for hypertension.
These modifications should include at least
150 minutes of moderate physical activity per
week and, for most patients, a reduction in
total calories, saturated fat, and sodium.
It is important to remind patients that
to maximize the benefits in terms of treating
hyperglycemia, hypertension, and dyslipid-
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emia, such changes must be maintained over
the long term.
❚ Aspirin therapy. The ADA also revised
its recommendation regarding aspirin therapy. Based on new evidence in the treatment
of women with ASCVD risk, the standards
now call for considering aspirin therapy
(75-162 mg/d) in both women and men
≥50 years as a primary prevention strategy
for those with type 1 or type 2 diabetes with
a 10-year ASCVD risk of >10%. (The previous
standards recommended this only for women older than 60 years.)
Antiplatelet therapy is now recommended for patients younger than 50 years with
multiple risk factors, and as secondary prevention in those with a history of ASCVD.19-21
❚ Hypertension. The ADA’s recommendations for treating hypertension in patients
with diabetes have not changed; the goal remains <140/<90 mm Hg. Lower targets may
be appropriate for younger patients, those
with albuminuria, and individuals with additional CVD risk factors; however, systolic
pressure <130 mm Hg has not been shown
to reduce CVD outcomes, and diastolic pressure <70 mm Hg has been associated with
higher mortality.22
Optimal medication and lifestyle therapy
are important to achieve goals, with avoidance of undue treatment burden. Angiotensin converting enzyme (ACE) inhibitors or
angiotensin receptor blockers (ARBs), but not
both, should be included as part of treatment.
Other agents, such as a thiazide diuretic, may
be needed to achieve individual goals. Serum creatinine/eGFR and serum potassium
levels should be monitored with the use of
diuretics.
❚ Lipids. The 2016 standards include notable changes in lipid management. The ADA
sees a role for ezetimibe for select patients,
based on studies such as the IMPROVE IT
trial23 that included participants with diabetes. The ADA also added a table highlighting
statin recommendations and delineating high
and moderate-intensity statins (TABLE 3).1
Those younger than 40 years with no other
risk factors may not need a statin, but patients ages 40 or older will need moderateto high-intensity statin therapy to effectively
lower ASCVD risk.24-28
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TABLE 2

Statin (or combination) therapy for which patients?1
Age

Risk factors

<40 years

None

None

ASCVD risk factor(s)†

Moderate or high

ASCVD

High

None

Moderate

ASCVD risk factors

High

ASCVD

High

ACS and LDL >50 mg/dL in an individual
who can’t tolerate high-dose statin

Moderate + ezetimibe

None

Moderate

ASCVD risk factors

Moderate or high

ASCVD

High

ACS and LDL >50 mg/dL in an individual
who can’t tolerate high-intensity statin

Moderate + ezetimibe

40–75 years

>75 years

Recommended statin intensity*

ACS, acute coronary syndrome; ASCVD, atherosclerotic cardiovascular disease; LDL, low-density lipoprotein.
*In addition to lifestyle therapy.
Risk factors include LDL cholesterol ≥100 mg/dL, high blood pressure, smoking, overweight or obesity, and a family history
of premature ASCVD.

†

These recommendations reflect a comprehensive plan to reduce ASCVD in this atrisk population, which should also include
lifestyle modification, including smoking
prevention and quit strategies, as needed.

Microvascular complications
› DIABETIC KIDNEY DISEASE

How should I diagnose nephropathy?
The ADA changed the terminology, referring
to “diabetic kidney disease” (DKD) rather
than nephropathy to highlight the fact that
the focus is on kidney disease directly linked
to diabetes.
Other recommendations include an
annual assessment of urinary albumin (eg,
spot urine albumin-to-creatinine ratio and
eGFR) for patients who have had type 1 diabetes for ≥5 years and all patients who have
type 2 diabetes. Two out of 3 abnormal specimens collected within a 3- to 6-month period indicate the presence of albuminuria.
What can be done to prevent or slow
the progression of DKD?
Optimal BP and glycemic control are key,29-35
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along with diet and medication. For patients
with DKD, dietary protein intake should be
0.8 g/kg body weight per day. ACE inhibitors and ARBs have been shown to slow the
decline in eGFR in patients with elevated urinary albumin excretion (>30 mg/day).
However, neither an ACE inhibitor nor
an ARB is recommended for the primary prevention of DKD in patients who have normal
BP, normal urine albumin-to-creatinine ratio
(<30 mg/g), and normal eGFR. In addition,
combined use of an ACE inhibitor and an
ARB should be avoided, as it provides no additional benefit and increases the risk of adverse effects.29

The ADA
sees a role
for ezetimibe
for select
patients, based
on studies
such as the
IMPROVE IT trial
that included
participants
with diabetes.

› RETINOPATHY
How should I manage retinopathy
in patients with diabetes?
As with the management of DKD, it is important to optimize glycemic and BP control
to reduce the risk, or slow the progression,
of retinopathy. Intensive diabetes management, with the goal of achieving nearnormal glycemic levels, has been shown
in large prospective randomized studies to
prevent or delay the onset and progression
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of diabetic retinopathy.33,36 The presence
of retinopathy is not a contraindication to
aspirin therapy for ASCVD prevention, as
aspirin does not increase the risk of retinal
hemorrhage.

TABLE 3

Statin drugs and daily dosage1
Moderate intensity (lowers LDL by 30%
to <50%):
Atorvastatin 10-20 mg

When should patients with diabetes
be screened for retinopathy?
Patients with type 1 diabetes should have an
initial dilated and comprehensive eye examination by an ophthalmologist or optometrist within 5 years of the onset of diabetes.
Those with type 2 diabetes should have such
an exam shortly after diagnosis. The exam
should be repeated annually; if there is no
evidence of retinopathy, however, 2-year intervals may be considered.

› PERIPHERAL NEUROPATHY

The presence
of retinopathy
is not a
contraindication
to aspirin
therapy for
atherosclerotic
cardiovascular
disease
prevention,
as aspirin does
not increase the
risk of retinal
hemorrhage.

When and how should I screen patients
with diabetes for neuropathy?
All patients should be screened for diabetic
peripheral neuropathy (DPN) starting at diagnosis of type 2 diabetes and 5 years after
the diagnosis of type 1 diabetes, and continued at least annually thereafter. Assessment
should include a detailed history and 10-g
monofilament testing, as well as at least one
of the following tests: pinprick, temperature,
and vibration sensation.
It is important, too, to screen patients
with more advanced diabetes for signs and
symptoms of autonomic neuropathy. Signs
and symptoms may include resting tachycardia, exercise intolerance, orthostatic
hypotension, gastroparesis, constipation,
impaired neurovascular function, and autonomic failure in response to hypoglycemia.
In men, diabetic autonomic neuropathy may
cause erectile dysfunction and/or retrograde
ejaculation.
How should I manage patients
who have DPN?
Tight glycemic control is the only measure
that has been shown to prevent or delay
the development of DPN or cardiac autonomic neuropathy in patients with type 1
diabetes,37,38 and to slow the progression
of neuropathy in some patients with type 2
diabetes.39
The FDA has approved pregabalin, du-
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Fluvastatin XL 80 mg
Lovastatin 40 mg
Pitavastatin 2-4 mg
Pravastatin 40-80 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
High intensity (lowers LDL by ≥50%):
Atorvastatin 40-80 mg
Rosuvastatin 5-10 mg
LDL, low-density lipoprotein.

loxetine, and tapentadol for the treatment
of pain associated with DPN. Tricyclic antidepressants, gabapentin, venlafaxine, carbamazepine, tramadol, and topical capsaicin,
although not approved for the treatment of
painful DPN, may also be effective in treating
neuropathic pain.
For those with autonomic neuropathy,
dietary changes and prokinetic agents such
as erythromycin may alleviate gastroparesis.
Due to extrapyramidal adverse effects, metoclopramide is reserved for the most severe
and unresponsive cases. Recurrent urinary
tract infections, pyelonephritis, incontinence, or palpable bladder should prompt
an evaluation for bladder dysfunction. Controlling lipids and BP, quitting smoking, and
making other lifestyle changes can reduce
both the development and the progression of
autonomic neuropathy.

› FOOT CARE/PERIPHERAL ARTERIAL
DISEASE
What does the ADA recommend regarding
foot care for patients with diabetes?
The ADA’s standards recommend an annual
comprehensive foot examination to identify
risk factors predictive of ulcers and potential
amputations. The exam should start with inspection and assessment of foot pulses and
should seek to identify loss of peripheral
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sensation. The examination should include
inspection of the skin, assessment of foot
deformities, neurologic assessment including 10-g monofilament testing and pinprick
or vibration testing or assessment of ankle
reflexes, and vascular assessment, including
pulses in the legs and feet.40
It is also important to screen patients for
peripheral arterial disease (PAD), with a comprehensive medical history and physical exam
of pulses. Ankle-brachial index testing (ABI)
should be performed in patients with signs or
symptoms of PAD, including claudication or
skin and hair changes in the lower extremities.
ABI may be considered for all patients with diabetes starting at age 50 and in those younger
than 50 years who have risk factors.41
Which patients with diabetes
are at higher risk for foot complications?
The following are risk factors for foot complications: previous amputation, prior foot
ulcer, peripheral neuropathy, foot deformity,
peripheral vascular disease, visual impairment, peripheral neuropathy (especially if on
dialysis), poor glycemic control, and smoking. Patients with high-risk foot conditions
should be educated about their risk and appropriate management.
A well-fitted walking shoe that cushions
the feet and redistributes pressure is one option to help patients. Patients with bony deformities may need extra wide or deep shoes

and patients with more advanced disease
may need custom-fitted shoes.
When should patients be referred
to a foot specialist?
Refer patients to a foot care specialist for
ongoing preventive care and lifelong surveillance if they smoke or have a history of
lower-extremity complications, a loss of protective sensation, structural abnormalities,
or PAD.

› IMMUNIZATION
Are there special immunization
recommendations for people
with diabetes?
No. Children and adults with diabetes should
be vaccinated according to age-related recommendations for the general population,
the standards state. The ADA also recommends that patients ages 19 to 59 years receive the hepatitis B vaccine if they haven’t
already done so and that the vaccine be
considered for those ≥60 years, as well. This
is in keeping with the Centers for Disease
Control and Prevention’s recommendation
that adults with any medical, occupational,
or other risk factor be immunized against
hepatitis B.42 			
JFP
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